FindMyKOL
Clinical trialNCT05409482RecruitingObservational

A Real-world Study of Camrelizumab Combined With Apatinib Mesylate in Unresectable Hepatocellular Carcinoma

NCT05409482 is an observational study sponsored by Meng Chao Hepatobiliary Hospital of Fujian Medical University. As of 18 Nov 2026, it is recruiting participants. It studies Hepatocellular Carcinoma. The registry lists an enrollment of 300 participants at 1 site in 1 country. The registry lists a start date of 20 Aug 2022 and a primary completion date of 1 Mar 2026. One of its registered investigators has a FindMyKOL profile.

SponsorMeng Chao Hepatobiliary Hospital of Fujian Medical UniversityEnrollment300Hepatocellular Carcinoma
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT05409482
FieldValue
Registry IDNCT05409482
StatusRecruiting
Study typeObservational study
Lead sponsorMeng Chao Hepatobiliary Hospital of Fujian Medical University
Enrollment300
Registered sites1
Countries1
ConditionsHepatocellular Carcinoma
Start20 Aug 2022
Primary completion1 Mar 2026
Study completion1 Mar 2026
Last update posted13 May 2025

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

To evaluate the efficacy and safety of camrelizumab combined with apatinib mesylate in the treatment of unresectable hepatocellular carcinoma.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

China1 site, 1 recruiting
  • Mengchao Hepatobiliary Hospital, Fujian Medical University

    Fuzhou, Fujian

    Recruiting

Sites by country

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study. It may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Questions about NCT05409482

Each answer restates registry values shown on this page.

What is NCT05409482?

NCT05409482 is an observational study sponsored by Meng Chao Hepatobiliary Hospital of Fujian Medical University. It studies Hepatocellular Carcinoma.

Is NCT05409482 recruiting?

As of 18 Nov 2026, it is recruiting participants. 1 of its 1 sites list their own status as recruiting.

Who leads NCT05409482?

The registry names Bo h Zhang (study director, Zhongshan Hospital (Xiamen), Fudan University), Cong r Wang (study director, Quanzhou First Hospital), Feng Lin (study director, Ningde Mindong Hospital) and 22 more officials as overall officials.

Where does NCT05409482 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: China.

When is NCT05409482 expected to complete?

The registry lists a primary completion date of 1 Mar 2026 and a study completion date of 1 Mar 2026. The sponsor last updated the record on 13 May 2025.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 18 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.